ENTITY

Freenome (FRNM US)

2
Analysis
Health Care • United States
Freenome, Inc. is an early cancer detection company that develops blood-based tests leveraging AI/ML to transform multi-cancer and multi-disease detection. This prospectus registers shares for resale by selling securityholders, from which the company will not receive proceeds.
more
bearish•Freenome
•21 Aug 2026 16:01

Freenome (FRNM US): Synthetic Expert Call Transcript (21 Aug 2026)

Primary Care Physicians (PCPs) will not adopt blood-based colorectal cancer (CRC) screening as a first-line option due to its poor advanced...

Share
bullish•Freenome
•20 Aug 2026 10:03

IPO Databook: Freenome (FRNM US) - Aug 2026

Freenome, Inc. is an early cancer detection company developing blood-based tests leveraging AI/ML to transform multi-cancer and multi-disease...

Share
x